Aptuit announces agreement with Regulus Therapeutics

Dr. Jonathan Goldman , CEO, Aptuit LLC, announced a strategic provider relationship between Aptuit, a leading Partnership Research Organization, and Regulus Therapeutics Inc, an innovative biopharmaceutical company. The agreement includes a broad range of discovery and development services to support Regulus programs targeting microRNAs.

Dr. Goldman stated, "Aptuit provides high quality standalone and integrated solutions in the target to candidate, and candidate to IND phases of development. Our scientific expertise and high standards in chemistry and biology improve the probability of success. In addition, our scale and fully integrated end to end approach reduces timeline and costs, and are an excellent fit with Regulus focus on microRNA. We believe our support will allow Regulus to rapidly progress more programs in parallel."

Dr. Timothy Wright , Regulus Chief R&D Officer, added: "Aptuit is recognized as a leading integrated service provider in the discovery and development space. We are delighted to engage Aptuit across multiple service areas to accelerate the progress of our most promising microRNA programs, achieving anticipated milestones and driving efficiency."

Dr. Goldman concluded, "Our mission is to help discover and develop new medicines with outstanding quality and world class scientific problem solving. Aptuit is committed to being the best-in-class provider of fully integrated drug discovery and development services, su pported by a culture of scientific excellence and innovation."